Ask AI
HCV Care in Nontraditional Settings

CE / CME

HCV Care in Nontraditional Settings: A Focus on Vulnerable Populations

Social Workers: 1.00 ASWB ACE CE Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: June 02, 2025

Expiration: June 01, 2026

Activity

Progress
1 2
Course Completed

References

  1. World Health Organization. Global health sector strategy on viral hepatitis, 2016-2021. who.int/publications/i/item/WHO-HIV-2016.06. Accessed May 6, 2025.
  2. Heffernan A, Cooke GS, Nayagam S, et al. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019;393:1319-1329.
  3. Centers for Disease Control and Prevention. 2024 national viral hepatitis progress report. cdc.gov/hepatitis/php/npr-2024/?CDC_AAref_Val=https://www.cdc.gov/hepatitis/policy/npr/2024/index.htm. Accessed May 6, 2025.
  4. US Department of Health and Human Services. Viral hepatitis national strategic plan. hhs.gov/hepatitis/viral-hepatitis-national-strategic-plan/index.html. Accessed May 6, 2025.
  5. CDC. 2022 Viral hepatitis surveillance report. cdc.gov/hepatitis-surveillance-2022/about/index.html. Accessed May 6, 2025.
  6. CDC. Viral hepatitis surveillance report 2021. cdc.gov/hepatitis/statistics/2021surveillance/hepatitis-c.htm. Accessed May 6, 2025.
  7. Falade-Nwulia O, Kelly SM, Amanor-Boadu S, et al. Hepatitis C in Black individuals in the US: a review. JAMA. 2023;330:2200-2208.
  8. American Association for the Study of Liver Disease and Infectious Diseases Society of America. HCV Guidance: recommendations for testing, managing, and treating hepatitis C. hcvguidelines.org. Accessed May 6 2025.
  9. Stone J, Fraser H, Lim AG, et al. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2018;18:1397-1409.
  10. Grebely J, Applegate TL, Cunningham P, et al. Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. Expert Rev Mol Diagn. 2017;17:1109-1115.
  11. van Dijk M, Drenth JPH; HepNed study group. Loss to follow-up in the hepatitis C care cascade: a substantial problem but opportunity for micro-elimination. J Viral Hepat. 2020;27:1270-1283.
  12. Bottero J, Boyd A, Gozlan J, et al. Simultaneous human immunodeficiency virus-hepatitis B-hepatitis C point-of-care tests improve outcomes in linkage-to-care: Results of a randomized control trial in persons without healthcare coverage. Open Forum Infect Dis. 2015;2:ofv162.
  13. Munang M, Smit E, Barnett T, et al. Outcomes and costs of single-step hepatitis C testing in primary care, Birmingham, United Kingdom. Public Health. 2019;166:40-44.
  14. Xpert HCV
  15. Grebely J. Point-of-care testing for hepatitis C infection: a critical building block for the foundation to achieve elimination. Clin Infect Dis. 2024;79:974-977.
  16. Trickey A, Fajardo E, Alemu D, et al. Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:253-270. 
  17. Sheehan Y, Cunningham EB, Cochrane A, et al. A “one-stop-shop” point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study. J Hepatol. 2023;79:635-644.
  18. Cunningham EB, Wheeler A, Hajarizadeh B, et al. Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:426-445.
  19. Centers for Disease Control and Prevention. Clinical screening and diagnosis for hepatitis C. cdc.gov/hepatitis-c/hcp/diagnosis-testing/. Accessed May 6, 2025.
  20. US Preventive Services Task Force. uspreventiveservicestaskforce.org/uspstf. Accessed May 6, 2025.
  21. Page K, Feinberg J. What hepatitis C virus (HCV) diagnostic tools are needed to advance diagnosis of current HCV infection in outreach settings and in a nonclinical setting? J Infect Dis. 2024;229:S328-S333.
  22. Rennert L, Howard KA, Kickham CM, et al. Implementation of a mobile health clinic framework for hepatitis C virus screening and treatment: a descriptive study. Lancet Reg Health Am. 2023;14;29:100648.
  23. Graham CS, Trooskin S. Universal screening for hepatitis C virus infection: a step toward elimination. JAMA. 2020;323:936-937.
  24. Chou R, Dana T, Fu R, et al. Screening for hepatitis C virus infection in adolescents and adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2020;323:1318.
  25. van Santen DK, Sacks-Davis R, Stewart A, et al. Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: findings from a multinational cohort between 2010 and 2019. EClinicalMedicine. 2022;56:101810.
  26. Solomon SS, Wagner-Cardoso S, Smeaton L, et al. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2022;7:307-317.
  27. Kattakuzhy S, Gross C, Emmanuel B, et al. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial. Ann Intern Med. 2017;167:311-318.
  28. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364:2199-207. 
  29. Rossaro L, Torruellas C, Dhaliwal S, et al. Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in Northern California. Dig Dis Sci. 2013;58:3620-3625.
  30. Miller L, Fluker SA, Osborn M, et al. Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic. J Natl Med Assoc. 2012;104:244-250.
  31. Degenhardt L, Charlson F, Stanaway J, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16:1385-1398. 
  32. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204:74-83.
  33. Zhou K, Fitzpatrick T, Walsh N, et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. Lancet Infect Dis. 2016;16:1409-1422.
  34. Herink MC, Seaman A, Leichtling G, et al. A randomized controlled trial for a peer-facilitated telemedicine hepatitis c treatment intervention for people who use drugs in rural communities: study protocol for the "peer tele-HCV" study. Addict Sci Clin Pract. 2023;18:35.
  35. Thompson WW, Symum H, Sandul A, et al. Vital Signs: hepatitis C treatment among insured adults—United States, 2019-2020. MMWR Morb Mortal Wkly Rep 2022;71:1011-1017.
  36. Hepatitis C Online. Addressing barriers to HCV treatment. hepatitisc.uw.edu/go/evaluation-treatment/addressing-structural-barriers-to-treatment/core-concept/all. Accessed May 6, 2025.
  37. Fluker SA, Darby R, McDaniel K, et al. Large-scale, primary care-based hepatitis C treatment in an urban, medically underserved patient population. Public Health Rep. 2024;139:163-168.
  38. Rosecrans AM, Cheedalla A, Rives ST, et al. Public health clinic-based hepatitis C treatment. Am J Prev Med. 2020;59:420-427.
  39. Eckhardt B, Mateu-Gelabert P, Aponte-Melendez Y, et al. Accessible hepatitis C care for people who inject drugs: a randomized clinical trial. JAMA Intern Med. 2022;182:494-502.
  40. Rosenthal ES, Silk R, Mathur P, et al. Concurrent initiation of hepatitis C and opioid use disorder treatment in people who inject drugs. Clin Infect Dis. 2020;71:1715-1722.
  41. Bobb R, Malayala SV, Ajayi E, et al. Hepatitis C treatment in persons who inject drugs in a medication assisted treatment program: a retrospective review of an integrated model. J Prim Care Community Health. 2023;14:21501319231164884.
  42. Talal AH, Markatou M, Liu A, et al. Integrated hepatitis C-opioid use disorder care through facilitated telemedicine: a randomized trial. JAMA. 2024;331:1369-1378.
  43. Masuda QN, Smith JE, Gaines J, et al. Outcomes of pharmacist-led treatment of hepatitis C in the Virginia Department of Corrections. J Correct Health Care. 2023;29:430-438.
  44. Sander G, Shirley-Beavan S, Stone K. The global state of harm reduction in prisons. J Correct Health Care. 2019;25:105-120.
  45. Kamarulzaman A, Reid SE, Schwitters A, et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet. 2016;388:1115-1126.
  46. Hedrich D, Alves P, Farrell M, et al. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction. 2012;107:501-517.
  47. The Hepatitis C Harm Reduction Project. Harm Reduction Coalition. Hepatitis C counseling best practice manual. naccho.org/uploads/downloadable-resources/Hepatitis-C-Counseling-Best-Practices-HRC.pdf. Accessed May 6, 2025.